Chemoradiotherapy for Patients With Oligometastatic Colorectal Cancer

Sponsor
Universitätsklinikum Hamburg-Eppendorf
Study ID
NCT01759238
Phase
PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Capecitabine — DRUG
    825mg/m2 per os bid
  • Bevacizumab — DRUG
    7.5 mg/kg
  • Radiotherapy — RADIATION
    (conventional or intensity-modulated and image-guided radiotherapy)

Study Details

This study tries to evaluate the role of chemoradiation with capecitabine and bevacizumab in oligometastatic patients neither being progressive nor resectable after chemotherapy.

Key Dates

First listed
Jan 3, 2013
Start date
May 31, 2013
Status verified
Jun 2022
Primary completion
Oct 31, 2014
Completion
Oct 31, 2014

Study Design

Enrollment
1 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Chemoradiation
    Chemoradiation with different radiotherapy regimes (depending on location and size of irradiated lesions; e.g. conventional radiotherapy with a total dose of 35 Gy, delivered in 2.5Gy fractions for 14 days or intensity-modulated and image-guided radiotherapy with a total dose of 40 Gy, delivered in 4.0 Gy fractions for 10 days or 3-8 fractions with 8-15 Gy) combined with bevacizumab (7.5mg/kg day 1) and capecitabine (825mg/m2 bid on day 1-5, 8-12 and 15-19)

Primary Outcome Measure

Progression free survival rate [ Time Frame: 12 months ]

Related Studies